WA
NBSE

WFG Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

WFG Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$3K Hold
10
– – ﹤0.01% 1386
2017
Q1 		$3K Hold
10
– – ﹤0.01% 1300
2016
Q4 		$6K Hold
10
– – ﹤0.01% 1238
2016
Q3 		$11K Hold
10
– – ﹤0.01% 1103
2016
Q2 		$11K Buy
+10
New +$12.6K ﹤0.01% 1077
2016
Q1 		– Sell
-3
Closed -$6K – 1713
2015
Q4 		$6K Buy
+3
New +$4.61K ﹤0.01% 1197

Other funds holding NBSE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

WFG Advisors's NBSE Position: Q2 2017 in Review

WFG Advisors held its NeuBase Therapeutics, Inc. Common Stock (NBSE) position steady in Q2 2017 at 10 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #1386.

WFG Advisors first reported a position in NBSE in Q4 2015 and has held it in 6 quarters since. The position peaked at $11K in Q3 2016. 38 funds tracked by Wall St. Rank hold NBSE as of Q2 2017.

  • WFG Advisors held 10 shares of NeuBase Therapeutics, Inc. Common Stock worth $3K as of Q2 2017.
  • WFG Advisors left its NeuBase Therapeutics, Inc. Common Stock share count unchanged in Q2 2017.
  • NeuBase Therapeutics, Inc. Common Stock made up ﹤0.01% of WFG Advisors's portfolio in Q2 2017, its #1386 holding.
  • WFG Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2015 and has held it in 6 quarters since.
  • WFG Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $11K in Q3 2016.
  • 38 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.